Dual Checkpoint Inhibition in Melanoma With ≥1% PD-L1—Time to Reassess the Evidence
Marco Donia, Vinay Prasad
Abstract
This Viewpoint discusses use of anti–PD-1 monotherapy as the primary treatment option for patients with treatment-naive metastatic melanoma staining positive for PD-L1 over dual checkpoint inhibition therapy.
Topics & Concepts
MedicineMelanomaOncologyPD-L1Metastatic melanomaInternal medicineDual (grammatical number)Cancer researchImmunotherapyCancerArtLiteratureCancer Immunotherapy and BiomarkersCAR-T cell therapy researchMelanoma and MAPK Pathways